Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raludotatug deruxtecan - Daiichi Sankyo

Next Previous
Drug Profile

Raludotatug deruxtecan - Daiichi Sankyo

Alternative Names: DS-6000; DS-6000a; MK-5909; R-DXd

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Merck & Co
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Renal cell carcinoma

Most Recent Events

  • 11 Apr 2025 Phase-I/II clinical trials in Fallopian tube cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06843447)
  • 11 Apr 2025 Phase-I/II clinical trials in Fallopian tube cancer (Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (IV) (NCT06843447)
  • 11 Apr 2025 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06843447)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top